| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Risperidone in the treatment of acute mania: double-blind, placebo-controlled study.
|
Br J Psychiatry
|
2005
|
2.52
|
|
2
|
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
|
Am J Psychiatry
|
2003
|
2.24
|
|
3
|
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
|
Int J Neuropsychopharmacol
|
2009
|
1.76
|
|
4
|
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
|
J Clin Psychiatry
|
2004
|
1.70
|
|
5
|
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
|
Schizophr Res
|
2007
|
1.68
|
|
6
|
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
|
J Clin Psychiatry
|
2003
|
1.66
|
|
7
|
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
|
Schizophr Res
|
2009
|
1.62
|
|
8
|
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.
|
Br J Psychiatry
|
2009
|
1.61
|
|
9
|
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
|
Biol Psychiatry
|
2007
|
1.58
|
|
10
|
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
|
J Clin Psychopharmacol
|
2007
|
1.46
|
|
11
|
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
|
Neuropsychopharmacology
|
2010
|
1.24
|
|
12
|
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.
|
Eur Neuropsychopharmacol
|
2005
|
1.06
|
|
13
|
Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.
|
J Clin Psychiatry
|
2004
|
1.03
|
|
14
|
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
|
Int Clin Psychopharmacol
|
2004
|
1.01
|
|
15
|
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
|
Int Clin Psychopharmacol
|
2008
|
1.01
|
|
16
|
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
|
Am J Geriatr Psychiatry
|
2008
|
0.96
|
|
17
|
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
|
J Psychopharmacol
|
2009
|
0.95
|
|
18
|
Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
|
Int J Neuropsychopharmacol
|
2005
|
0.92
|
|
19
|
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
|
Int J Geriatr Psychiatry
|
2004
|
0.89
|
|
20
|
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
|
Eur Neuropsychopharmacol
|
2006
|
0.87
|
|
21
|
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.
|
Br J Psychiatry
|
2005
|
0.84
|
|
22
|
A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures.
|
Epilepsia
|
2011
|
0.84
|
|
23
|
Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study.
|
Int Clin Psychopharmacol
|
2011
|
0.80
|
|
24
|
One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia.
|
CNS Spectr
|
2010
|
0.80
|
|
25
|
An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.
|
Int Clin Psychopharmacol
|
2006
|
0.79
|
|
26
|
Tramadol article conclusion troubling.
|
Pain Physician
|
2014
|
0.75
|
|
27
|
Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders.
|
Psychopharmacology (Berl)
|
2005
|
0.75
|